Chugai was founded in 1925 and developed into one of Japan's leading biotech companies in the 1990s, launching Epogin (1990) and Neutrogin (1991). In 2002, Chugai merged with Roche’s small-molecule Japan affiliate, Nippon Roche, and Roche became the parent company, now owning approximately 60% of the shares.
Chugai is developing cutting-edge antibody technologies and midsize molecules that have the potential to change treatment paradigms that older modalities cannot address.
Despite its early success, Hemlibra is now facing challenges from competitors with longer-acting drugs, or drugs that are more effective at preventing bleeding events.
|
Metric
|
4519
|
4568
|
4502
|
|---|---|---|---|
Price/Earnings (Normalized) | 21.17 | 18.69 | 48.22 |
Price/Book Value | 5.01 | 2.93 | 1.20 |
Price/Sales | 7.57 | 2.39 | 1.96 |
Price/Cash Flow | 19.10 | 38.02 | 10.96 |
|
Metric
|
4519
|
4568
|
4502
|
|---|---|---|---|
Quick Ratio | 3.43 | 1.46 | 0.54 |
Current Ratio | 4.35 | 2.42 | 1.14 |
Interest Coverage | 9,780.06 | 28.88 | 0.07 |
|
Metric
|
4519
|
4568
|
4502
|
|---|---|---|---|
Return on Assets (Normalized) | 19.65% | — | 5.53% |
Return on Equity (Normalized) | 23.42% | — | 11.34% |
Return on Invested Capital (Normalized) | 23.42% | — | 7.74% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|dThYHl? | LOCK|m@ | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|@J%%#<H | LOCK|QRq | $623B | |||
| AbbVie Inc
ABBV
| LOCK|####kV? | LOCK|$ww | $459B | |||
| Merck & Co Inc
MRK
| LOCK|G&gk?Tf | LOCK|?m | $355B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|qPvvC<r | LOCK|K! | $334B | |||
| Novartis AG ADR
NVS
| LOCK|RzQCvj! | LOCK|gw | $268B | |||
| AstraZeneca PLC
AZN
| LOCK|<VQ$?$H | LOCK|?p | $248B | |||
| Amgen Inc
AMGN
| LOCK|%&!xFqJ | LOCK|FK? | $220B | |||
| Gilead Sciences Inc
GILD
| LOCK|NGb@@@H | LOCK|SK | $183B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|m%j#@lH | LOCK|&Bp | $167B |
United States